Stocknear Logo Stocknear
/
Popular
Login

Aquestive Therapeutics In...

3.24
0.03 (0.93%)
At close: Mar 24, 2025, 3:59 PM
3.25
0.46%
After-hours: Mar 24, 2025, 07:58 PM EDT
0.93%
Bid 3.21
Market Cap 320.34M
Revenue (ttm) 62.4M
Net Income (ttm) -47.85M
EPS (ttm) -0.51
PE Ratio (ttm) -6.35
Forward PE -5.84
Analyst Buy
Ask 3.3
Volume 1,174,997
Avg. Volume (20D) 1,688,963
Open 3.26
Previous Close 3.21
Day's Range 3.21 - 3.35
52-Week Range 2.24 - 5.80
Beta 2.76

About AQST

Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral ...

[Show more]
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
IPO Date Jul 25, 2018
Employees 142
Stock Exchange NASDAQ
Ticker Symbol AQST
Website https://www.aquestive.com
Full Company Profile

Analyst Forecast

According to 7 analyst ratings, the average rating for AQST stock is "Buy." The 12-month stock price forecast is $9.5, which is an increase of 193.21% from the latest price.

Stock Forecasts

Next Earnings Release

Aquestive Therapeutics Inc. is scheduled to release its earnings on May 6, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
2 weeks ago
+2.2%
Aquestive Therapeutics shares are trading lower af... Unlock content with Pro Subscription
3 months ago
+5.2%
Aquestive Therapeutics shares are trading higher after the company announed the FDA has granted seven years of orphan drug exclusivity to Libervant Buccal Film for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity that are distinct from a patient's usual seizure pattern in patients with epilepsy between two to five years of age.
news image

2 weeks ago · seekingalpha.com

Aquestive Therapeutics, Inc. (AQST) Q4 2024 Earnings Call Transcript

Aquestive Therapeutics, Inc. (NASDAQ:AQST ) Q4 2024 Results Conference Call March 6, 2025 8:00 AM ET Company Participants Brian Korb - IR Dan Barber - CEO Ernie Toth - CFO Sherry Korczynski - SVP of S...

news image

2 weeks ago · zacks.com

Compared to Estimates, Aquestive Therapeutics (AQST) Q4 Earnings: A Look at Key Metrics

The headline numbers for Aquestive Therapeutics (AQST) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wa...

news image

2 weeks ago · zacks.com

Aquestive Therapeutics (AQST) Reports Q4 Loss, Lags Revenue Estimates

Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.12 per share a year ago.

news image

2 months ago · seekingalpha.com

Aquestive Therapeutics: Five Foci For 2025

Aquestive Therapeutics' Anaphylm is nearing FDA approval, potentially disrupting the U.S. anaphylaxis market dominated by EpiPen, with peak sales estimated at $300–400M. AQST-108, a topical epinephrin...

Create Price Alert on AQST

Your price alert will notify you when the stock price is above 3.24.

Add to Watchlist